⚠️ FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN USE.

MOTS-C — Published Research

Written by: Chameleon Peptides Editorial Team Reviewed by: Chameleon Peptides Research Team Last reviewed: March 28, 2026

← Back to MOTS-C product page

Compound Overview: MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid mitochondrial-derived peptide (MDP) with the sequence MRWQEMGYIFYPRKLR. Molecular weight: 2174.69 Da. MOTS-c is encoded within the mitochondrial 12S rRNA gene and functions as a retrograde signaling molecule from the mitochondria to the nucleus. It is a key regulator of metabolic homeostasis, primarily acting through AMPK (5′-adenosine monophosphate-activated protein kinase) pathway activation.

Discovery of MOTS-c as a Mitochondrial-Derived Peptide Regulating Metabolic Homeostasis

The landmark 2015 study by Lee et al. identified MOTS-c as a novel short open reading frame (sORF) encoded within the mitochondrial 12S rRNA gene. Researchers demonstrated that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. The peptide’s primary target organ was identified as skeletal muscle, where it inhibits the folate cycle and its tethered de novo purine biosynthesis pathway, leading to activation of AMPK. This discovery established MOTS-c as the first mitochondrial-encoded peptide shown to actively regulate metabolic homeostasis at both the cellular and organismal level.

Citation: Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009. PubMed PMID: 25738459


MOTS-c as a Regulator of Plasma Metabolites and Insulin Sensitivity in Obese Models

Kim et al. (2019) used an unbiased metabolomics approach to examine the effect of MOTS-c on plasma markers of metabolic dysfunction in diet-induced obese (DIO) mice. The study found that MOTS-c injection reduced three key metabolic pathways — sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism — all of which are typically upregulated in obese and type 2 diabetes models. The data demonstrated that MOTS-c improves insulin sensitivity and increases beta-oxidation to prevent fat accumulation, providing a mechanistic understanding of how the peptide reduces body weight and ameliorates fatty liver in DIO mice.

Citation: Kim SJ, Miller B, Kumagai H, Silverstein AR, Flores M, Cohen P. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. doi:10.14814/phy2.14171. PubMed PMID: 31293078


MOTS-c: A Novel Mitochondrial-Derived Peptide Regulating Muscle and Fat Metabolism

This comprehensive review by Lee et al. (2016) characterized MOTS-c as a mitochondrial-derived peptide hormone with broad metabolic implications. The authors detailed how MOTS-c targets skeletal muscle and enhances glucose metabolism, with implications for the regulation of obesity, diabetes, exercise physiology, and longevity. The review positioned MOTS-c within the broader framework of mitochondrial-derived peptides (MDPs) alongside humanin, establishing the concept that mitochondria function not merely as metabolic organelles but as active signaling units that encode hormone-like peptides capable of regulating metabolism within and between cells.

Citation: Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016;100:182-187. doi:10.1016/j.freeradbiomed.2016.05.015. PubMed PMID: 27216708


MOTS-c Nuclear Translocation and Gene Expression Regulation Under Metabolic Stress

Kim et al. (2018) made the groundbreaking discovery that MOTS-c, a peptide encoded in the mitochondrial genome, translocates to the nucleus and regulates nuclear gene expression following metabolic stress. This nuclear translocation occurs in an AMPK-dependent manner. In the nucleus, MOTS-c regulated a broad range of genes in response to glucose restriction, including those with antioxidant response elements (ARE), and interacted with ARE-regulating stress-responsive transcription factors such as NFE2L2/NRF2. These findings indicate that the mitochondrial and nuclear genomes co-evolved to independently encode factors that cross-regulate each other, representing a paradigm shift in understanding mito-nuclear communication.

Citation: Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008. PubMed PMID: 29983246


MOTS-c as an Exercise-Induced Regulator of Age-Dependent Physical Decline

Lai et al. (2021) provided evidence that MOTS-c functions as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. The study demonstrated that late-life initiated intermittent MOTS-c treatment (3x/week, beginning at 23.5 months of age) increased physical capacity and healthspan in aged mice. Critically, the researchers showed that in humans, exercise induces endogenous MOTS-c expression in both skeletal muscle (11.9-fold increase) and in circulation (1.5-fold increase). These findings established MOTS-c as a mitochondrial-encoded exercise factor and a potential target for age-related physical decline.

Citation: Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. doi:10.1038/s41467-020-20790-0. PubMed PMID: 33473109

Disclaimer: This page is provided for educational and informational purposes only. MOTS-c is a research compound intended for laboratory use only. The studies summarized above were conducted in animal models and in vitro systems. This information does not constitute medical advice and should not be interpreted as a recommendation for human use. MOTS-c is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Chameleon Peptides sells research compounds strictly for scientific investigation purposes.

Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.